|Titre :||Is Vancouver Canada's supervised injection facility cost-saving? (2010)|
|Auteurs :||S. D. PINKERTON|
|Type de document :||Article : Périodique|
|Dans :||Addiction (Vol.105, n°8, August 2010)|
|Article en page(s) :||1429-1436|
|Discipline :||SAN (Santé publique / Public health)|
Thésaurus TOXIBASESALLE DE CONSOMMATION A MOINDRE RISQUE ; REDUCTION DE CONSOMMATION ; MODELE STATISTIQUE ; VIH ; INFECTION ; COUT ; EFFICACITE ; ECHANGE DE SERINGUES
OBJECTIVE: To determine whether Vancouver's Insite supervised injection facility and syringe exchange programs are cost-saving--that is, are the savings due to averted HIV-related medical care costs sufficient to offset Insite's operating costs?
METHODS: The analyses examined the impact of Insite's programs for a single year. Mathematical models were used to calculate the number of additional HIV infections that would be expected if Insite were closed. The life-time HIV-related medical costs associated with these additional infections were compared to the annual operating costs of the Insite facility.
RESULTS: If Insite were closed, the annual number of incident HIV infections among Vancouver IDU would be expected to increase from 179.3 to 262.8. These 83.5 preventable infections are associated with $17.6 million (Canadian) in life-time HIV-related medical care costs, greatly exceeding Insite's operating costs, which are approximately $3 million per year.
CONCLUSIONS: Insite's safe injection facility and syringe exchange program substantially reduce the incidence of HIV infection within Vancouver's IDU community. The associated savings in averted HIV-related medical care costs are more than sufficient to offset Insite's operating costs.
|Domaine :||Drogues illicites / Illicit drugs|
|Affiliation :||Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI, USA|